Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta A4 precursor protein-binding family A member 1 (APBA1, also known as X11 or MINT1) is a neuronal adaptor protein primarily expressed in the brain, where it interacts with the C-terminus of the amyloid precursor protein (APP). APBA1 stabilizes APP at the cell surface and inhibits its proteolytic cleavage, reducing generation of amyloid-beta peptide, which is implicated in the pathology of Alzheimer’s disease. As a member of the X11/Mint family, APBA1 is a multidomain scaffold protein containing a PTB domain and PDZ domains, enabling formation of multiprotein complexes involved in synaptic vesicle exocytosis, neuronal signaling, and synaptic plasticity. APBA1 is implicated in coupling vesicle exocytosis to cell adhesion at synapses, further influencing neurotransmitter release and neuronal connectivity. Loss or alteration of APBA1 disrupts these processes and is linked to altered APP processing, beta-amyloid accumulation, and synaptic dysfunction relevant to neurodegenerative disease, particularly Alzheimer’s disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid beta A4 precursor protein-binding family A member 1 (APBA1).